Improving evaluations and management of the appropriate application of modern anticancer drug therapy

Introduction. Evaluation and further improvement of the use of resources of the oncological service (including drug therapy) can lead to a subsequent qualitative gain in the availability of new types of effective antitumor technologies for a larger number of patients with severe oncological pathology. The experience of the Netherlands in managing the cancer care is useful for the local regional health services.

Purpose of the study. Study of approaches to economically and clinically feasible use of anticancer therapy in real hospital practice.

Material and methods. The scientific study was performed on the base of the search results in the databases of the Dutch digital educational platform, in the PubMed/Medline database and the Google search engine. The queries used the words: doelmatigheid, kanker, doelgerichte therapie, rationality, cancer, targeted therapy, etc. We analyzed the results published in 2021–2022.

Results. There hаve bеen  studied methods for increasing the expediency of clinical application of therapeutic regimens in oncology including a) rationalization of chemotherapy regimens; b) ensuring the mobility of patients receiving chemotherapy: chemotherapy on the principle of “connect and go” technology, self-administration of anticancer drugs; c) lean use of immunotherapy: drug therapy shelf life extension, vial count rounding and immunotherapy hybrid dosing; justified reduction in the duration of the course of immunotherapy.

Limitations. In general, initiatives being put forward to improve the appropriateness of anticancer therapy should be previously tested in pilot projects.

Conclusions. If positive opinions are received from expert institutions and regulatory authorities based on the results of pilot projects, innovative schemes for the appropriate use of drugs can be included in the list of services and programs reimbursed by the health insurer on an ongoing basis.

Compliance with ethical standards. The study does not require submission the opinion of the biomedical ethics committee or other documents.

Contribution of the authors:
Andreev D.A. — material collection and processing, collection of literature data, compilation of the list of literature, writing the text;
Zavyalov A.A. — research concept and design, editing.
All authors are responsible for the integrity of all parts of the manuscript and approval of its final version.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: July 18, 2022 
Accepted: September 07, 2022
Published: December 12, 2022